PURPOSE: We report the treatment and outcome of patients with peripheral primitive neuroectodermal tumor (PNET) and extraosseous Ewing's tumor (EOE) using Ewing's-directed therapy, including an ifosfamide and etoposide window. METHODS: Seventeen pediatric patients with peripheral PNET (n = 14) or EOE (n = 3) were enrolled between 1988 and 1992 on our institutional Ewing's protocol. Induction therapy comprised a 9-week "window" of ifosfamide and etoposide, followed by 9 weeks of therapy with cyclophosphamide and Adriamycin (Adria Laboratories, Columbus, OH). Response assessment after 17 weeks was followed by surgery and/or radiotherapy (doses based on tumor size and response to induction), repeat evaluation, and maintenance chemotherapy with alternating courses of vincristine/dactinomycin, ifosfamide/etoposide, and cyclophosphamide/Adriamycin for a total of 45 weeks. RESULTS: At diagnosis, 8 patients had large lesions (>8 cm) and 3 had pulmonary metastases (1 with large tumor). Surgical resection was performed at diagnosis for 9 patients and after induction therapy for 5. During window therapy, all of the 9 evaluable patients responded (8 partial, I objective), and no patient without measurable disease developed disease progression. Responses were maintained or improved during subsequent induction in six of the patients with residual disease. Fourteen patients received local radiotherapy. At 49 to 94 months after diagnosis, 12 patients are disease-free (1 in second remission), 4 have died, and 1 is alive with disease. The five-year overall and progression-free survival rates are 77 +/- 13% and 62 +/- 16%, respectively. CONCLUSION: The use of consistent Ewing's-directed combined-modality therapy for patients with soft tissue peripheral PNET/EOE results in survival similar to that of patients with osseous Ewing's tumor. The combination of ifosfamide and etoposide appears active and should be incorporated in future treatment protocols.
PURPOSE: We report the treatment and outcome of patients with peripheral primitive neuroectodermal tumor (PNET) and extraosseous Ewing's tumor (EOE) using Ewing's-directed therapy, including an ifosfamide and etoposide window. METHODS: Seventeen pediatric patients with peripheral PNET (n = 14) or EOE (n = 3) were enrolled between 1988 and 1992 on our institutional Ewing's protocol. Induction therapy comprised a 9-week "window" of ifosfamide and etoposide, followed by 9 weeks of therapy with cyclophosphamide and Adriamycin (Adria Laboratories, Columbus, OH). Response assessment after 17 weeks was followed by surgery and/or radiotherapy (doses based on tumor size and response to induction), repeat evaluation, and maintenance chemotherapy with alternating courses of vincristine/dactinomycin, ifosfamide/etoposide, and cyclophosphamide/Adriamycin for a total of 45 weeks. RESULTS: At diagnosis, 8 patients had large lesions (>8 cm) and 3 had pulmonary metastases (1 with large tumor). Surgical resection was performed at diagnosis for 9 patients and after induction therapy for 5. During window therapy, all of the 9 evaluable patients responded (8 partial, I objective), and no patient without measurable disease developed disease progression. Responses were maintained or improved during subsequent induction in six of the patients with residual disease. Fourteen patients received local radiotherapy. At 49 to 94 months after diagnosis, 12 patients are disease-free (1 in second remission), 4 have died, and 1 is alive with disease. The five-year overall and progression-free survival rates are 77 +/- 13% and 62 +/- 16%, respectively. CONCLUSION: The use of consistent Ewing's-directed combined-modality therapy for patients with soft tissue peripheral PNET/EOE results in survival similar to that of patients with osseous Ewing's tumor. The combination of ifosfamide and etoposide appears active and should be incorporated in future treatment protocols.
Authors: David Boyce-Fappiano; B Ashleigh Guadagnolo; Ravin Ratan; Wei-Lien Wang; Michael J Wagner; Shreyaskumar Patel; John A Livingston; Patrick P Lin; Kevin Diao; Devarati Mitra; Ahsan Farooqi; Alexander J Lazar; Christina L Roland; Andrew J Bishop Journal: Oncologist Date: 2020-12-14
Authors: Mark A Applebaum; Jennifer Worch; Katherine K Matthay; Robert Goldsby; John Neuhaus; Daniel C West; Steven G Dubois Journal: Cancer Date: 2011-01-10 Impact factor: 6.860
Authors: Thomas Cash; Elizabeth McIlvaine; Mark D Krailo; Stephen L Lessnick; Elizabeth R Lawlor; Nadia Laack; Joel Sorger; Neyssa Marina; Holcombe E Grier; Linda Granowetter; Richard B Womer; Steven G DuBois Journal: Pediatr Blood Cancer Date: 2016-06-14 Impact factor: 3.167
Authors: Ahmed Mohammed Morsy; Salah Abdel-Hadi; Khalid Mohammed Rezk; Gamal Amira; Badawy Mohammed Ahmed; Marwa Tammam Hussien; Mahmoud Gamal Ameen; Hosam Eldein Mostafa Kamel; Doaa Mohamed Fouad; Alia Mohamed Attia; Asmaa Salah; Osama Mostafa Abd Elbadee; Ayatallah Ali Yousseif; Marwa Ismail Abdelgawad; Asmaa Hussein Fathy; Yasmine Nagy Elwany; Islam Karam-Allah Ramadan; Khaled Hassan Mosallam; Ahmed Ibrahim Abd Elwahab; Khaled Hashim Mahmoud; Maged Abdel Fattah Amine; Ahmed Refaat Abd Elzaher; Hanan Ahmed Eltyb; Ahmed Mubarak Hefni Journal: Am J Cancer Res Date: 2021-06-15 Impact factor: 6.166